Top

Published in:

01-12-2020 | Editorial

Cardiovascular risk assessment models: Have we found the perfect solution yet?

Authors: Aiden Abidov, MD, PhD, Omar Chehab, MD, MSc

Published in: Journal of Nuclear Cardiology | Issue 6/2020

Excerpt

Despite technical and pharmaceutical advancements and achievements in the last two decades and some decrease in overall mortality rate from cardiovascular disease (CVD), it remains the leading cause of death and economic burden.1 …

Benjamin EJ, et al. Heart disease and stroke statistics-2018 update: A report From the American Heart Association. Circulation 2018;137:e67-492.PubMed

Frohlich ED, Quinlan PJ. Coronary heart disease risk factors: Public impact of initial and later-announced risks. Ochsner J 2014;14:532-7.PubMedPubMedCentral

Willadsen TG, et al. The role of diseases, risk factors and symptoms in the definition of multimorbidity: A systematic review. Scand J Prim Health Care 2016;34:112-21.PubMedPubMedCentral

Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.PubMed

Hobbs FD, et al. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 2010;103:727-39.PubMed

Graham I, et al. European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14:S1-113.PubMed

British Cardiac S, et al. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-52.

Chaturvedi N. Ethnic differences in cardiovascular disease. Heart 2003;89:681-6.PubMedPubMedCentral

Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: A systematic review. Ethn Dis 2007;17:143-52.PubMed

10.

Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: An update. Clin Chem 2012;58:72-82.PubMed

11.

Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006;113:2335-62.PubMed

12.

Jin J. Risk assessment for cardiovascular disease with nontraditional risk factors. JAMA 2018;320:316.PubMed

13.

Bonner C, et al. Clinical validity, understandability, and actionability of online cardiovascular disease risk calculators: Systematic review. J Med Internet Res 2018;20:e29.PubMedPubMedCentral

14.

Beswick AD, et al. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease (supplement). London: Royal College of General Practitioners; 2008.

15.

Naghavi M, et al. From vulnerable plaque to vulnerable patient: Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006;98:2H-15H.PubMed

16.

Shaw LJ, et al. A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiology: Part II. J Nucl Cardiol 1997;4:52-60.PubMed

17.

Shaw LJ, et al. A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiology: Part I. J Nucl Cardiol 1996;3:538-45.PubMed

18.

Abidov A, Raff GL. Value of coronary CTA in patients with known or suspected CAD and non-diagnostic initial myocardial perfusion testing: Current evidence and clinical considerations. J Nucl Cardiol 2010;17:1101-6.PubMed

19.

Martineau P, Goertzen A, Leslie W. CRAX: A simple cardiovascular risk assessment tool to predict risk of acute myocardial infarction or death. J Nucl Cardiol 2018. https://doi.org/10.1007/s12350-018-01556-0.CrossRefPubMedPubMedCentral

20.

Betancur J, et al. Prognostic value of combined clinical and myocardial perfusion imaging data using machine learning. JACC Cardiovasc Imaging 2018;11:1000-9.PubMed

21.

Koh AS, et al. Differential risk reclassification improvement by exercise testing and myocardial perfusion imaging in patients with suspected and known coronary artery disease. J Nucl Cardiol 2016;23:366-78.PubMed

22.

Shaw LJ, et al. Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT. JACC Cardiovasc Imaging 2010;3:1139-48.PubMed

23.

Osawa K, Nakanishi R, Budoff M. Coronary artery calcification. Glob Heart 2016;11:287-93.PubMed

24.

Detrano R, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-45.PubMed

25.

Lakoski SG, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: The multi-ethnic study of atherosclerosis (MESA). Arch Intern Med 2007;167:2437-42.PubMed

26.

Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.PubMed

27.

Pencina MJ, et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72 (discussion 207-12).PubMed

28.

Hlatky MA, et al. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation 2009;119:2408-16.PubMedPubMedCentral

29.

Karlamangla AS, et al. Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001-2006. Ann Epidemiol 2010;20:617-28.PubMedPubMedCentral

30.

Hunt KJ, et al. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study-evidence against the “Hispanic paradox”. Am J Epidemiol 2003;158:1048-57.PubMed

31.

Mensah GA, et al. State of disparities in cardiovascular health in the United States. Circulation 2005;111:1233-41.PubMed

32.

Meadows TA, et al. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc 2011;86:960-7.PubMedPubMedCentral

33.

Rana JS, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol 2016;67:2118-30.PubMedPubMedCentral

34.

Jr. Smith SC, Grundy SM. ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol 2014;64:601-12.PubMed

35.

Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: The roles of statins, revascularizations, and underascertainment in the Women’s Health Study. JAMA Intern Med 2014;174:1964-71.PubMedPubMedCentral

36.

Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5.PubMed

37.

DeFilippis AP, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015;162:266-75.PubMedPubMedCentral

38.

Yadlowsky S, et al. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9.PubMed

39.

Slomka PJ, et al. Cardiac imaging: Working towards fully-automated machine analysis and interpretation. Expert Rev Med Devices 2017;14:197-212.PubMedPubMedCentral

40.

D’Agostino RB Sr, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008;117:743-53.PubMed

41.

Kannel WB, et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;110:281-90.PubMed

42.

Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health Nations Health 1951;41:279-81.PubMedPubMedCentral

43.

D’Agostino RB Sr, et al. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.PubMed

44.

Hippisley-Cox J, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. BMJ 2007;335:136.PubMedPubMedCentral

45.

Hippisley-Cox J, et al. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.PubMedPubMedCentral

46.

Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ 2017;357:j2099.PubMedPubMedCentral

47.

Minhas JS, Patel P, Gupta PK. Limitations of a cardiac risk (QRISK2) calculator in patients with high density lipoprotein (HDL). High Blood Press Cardiovasc Prev 2016;23:47-50.PubMed

48.

Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study. BMJ 2009;339:b2584.PubMedPubMedCentral

49.

Woodward M, et al. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.PubMed

50.

Conroy RM, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.PubMed

51.

Organization WH. Prevention of cardiovascular disease guidelines for assessment and management of cardiovascular risk. Genenva: WHO; 2007.

52.

Otgontuya D, et al. Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. BMC Public Health 2013;13:539.PubMedPubMedCentral

53.

Selvarajah S, et al. Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol 2014;176:211-8.PubMed

54.

Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.PubMed

55.

Goff DC Jr, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines. Circulation 2014;129:S49-73.PubMed

56.

Board J. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl 2):1-67.

Title: Cardiovascular risk assessment models: Have we found the perfect solution yet?
Authors: Aiden Abidov, MD, PhD
Omar Chehab, MD, MSc
Publication date: 01-12-2020
Publisher: Springer International Publishing
Published in: Journal of Nuclear Cardiology / Issue 6/2020
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-019-01642-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cardiovascular risk assessment models: Have we found the perfect solution yet?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Myocardial blood flow assessment with SPECT systems: The renovation continues

The forgotten right ventricle in cardio-oncology

Revival of an old stressor: Dobutamine-stimulation for PET myocardial perfusion imaging in patients with end-stage liver disease?

Ventricular synchrony is not significantly determined by absolute myocardial perfusion in patients with chronic heart failure: A 13N-ammonia PET study

Somatostatin analogue scintigraphy in myocardial inflammation: An interesting image

CME INSTRUCTIONS: Hybrid PET/MR Imaging in Myocardial Inflammation Post-myocardial Infarction